[Research advances of M3 receptor: a new target for treating and preventing cardiovascular disease]

Insights

The M3 receptor, a muscarinic acetylcholine receptor, shows protective effects on the heart. This review explores its role in cardiovascular disease and potential as a therapeutic target.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Cardiovascular diseases (CVDs) pose significant global health risks due to high morbidity and mortality.
  • The M3 receptor, a subtype of muscarinic acetylcholine receptors (mAChRs), has emerged as a key focus in cardiovascular research.
  • Understanding the M3 receptor's function is crucial for developing novel therapeutic strategies against CVDs.

Purpose of the Study:

  • To review the multifaceted roles of the M3 receptor in cardiac function.
  • To elucidate the influence of the M3 receptor on various cardiovascular diseases.
  • To explore the underlying molecular mechanisms through which the M3 receptor exerts its effects.

Main Methods:

  • Literature review of existing research on M3 receptor in cardiovascular contexts.
  • Analysis of studies detailing the M3 receptor's physiological effects on the heart.
  • Synthesis of data on the M3 receptor's involvement in the pathophysiology of cardiovascular diseases.

Main Results:

  • The M3 receptor demonstrates significant cardioprotective properties.
  • Evidence suggests the M3 receptor plays a critical role in modulating cardiac function and mitigating cardiovascular damage.
  • Specific molecular pathways activated by the M3 receptor have been identified.

Conclusions:

  • The M3 receptor represents a promising therapeutic target for cardiovascular diseases.
  • Further research into M3 receptor signaling pathways could unlock new treatment avenues.
  • Targeting the M3 receptor offers potential for improved cardiovascular health outcomes.

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
6.0K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.6K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
2.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.5K